Neoleukin Therapeutics, Inc. (NLTX) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Quote Panel

Updated October 22, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
8.20M
Shares Outstanding
2.35M
Share in Float
1.36M
Dividende
0

Earning Date
No Data
Price Target
3.49
Average Volume
5520
Beta
1.102

Range
3.42-18.8
Industry
Drug Manufacturers - Specialty & Generic
Website
https://www.neoleukin.com
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

1.20x

P/S Ratio

0.27x

P/B Ratio

0.0

Debt/Equity

-1657.5%

Net Margin

$-12.3

EPS

How NLTX compares to sector?

P/E Ratio

Relative Strength

NLTX

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

N/A

N/A

2025-Revenue

$3.63

-245%

2025-EPS

N/A

N/A

2025-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Hold

Price Target

N/A(N/A)

Number of analyst

N/A

Last analyst upgrade/downgrade

Guggenheim

downgrade

Previous: Not converted

2022-11-15

Now: Neutral

Jefferies

initialise

Previous: Not converted

2022-09-12

Now: Buy

Earnings Growth

YoY

Current

Estimates

Q1.23

N/A

-1.00
vs -1.40

Q2.23

N/A

-0.20
vs -1.40

Q3.23

N/A

-0.41
vs -1.20

Q4.23

N/A

NA
vs NA

Q1.24

N/A

NA
vs NA

Q2.24

N/A

NA
vs -0.20

Q3.24

N/A

NA
vs -0.41

Q4.24

N/A

NA
vs NA

Q1.25

N/A

NA
vs NA

Q2.25

N/A

NA
vs NA

Sales Growth

YoY

Current

Estimates

Q1.23

NA

NA vs NA

Q2.23

NA

NA vs NA

Q3.23

NA

NA vs NA

Q4.23

NA

NA vs NA

Q1.24

NA

NA vs NA

Q2.24

NA

NA vs NA

Q3.24

NA

NA vs NA

Q4.24

NA

6.8M vs NA

Q1.25

NA

NA vs NA

Q2.25

NA

NA vs NA

Return on Equity

QoQ

Q1.23

-17%

-0.17
vs -0.14

Q2.23

-3%

-0.03
vs -0.17

Q3.23

-6%

-0.06
vs -0.03

Q4.23

NA

NA
vs NA

Q1.24

NA

NA
vs NA

Q2.24

-12%

-0.12
vs -0.06

Q3.24

-15%

-0.15
vs -0.12

Q4.24

-16%

-0.16
vs -0.15

Q1.25

-8%

-0.08
vs -0.16

Q2.25

-8%

-0.08
vs -0.08

Institutionnal Ownership

QoQ

Q1.21

86

86
vs 88

-2%

Q2.21

86

86
vs 86

NA

Q3.21

84

84
vs 86

-2%

Q4.21

82

82
vs 84

-2%

Q1.22

80

80
vs 82

-2%

Q2.22

58

58
vs 80

-27%

Q3.22

48

48
vs 58

-17%

Q4.22

46

46
vs 48

-4%

Q1.23

37

37
vs 46

-20%

Q2.23

37

37
vs 37

NA

Earnings Growth

Latest News

NLTX

businesswire.com

7 hours ago

NLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to Shareholders

NLTX

globenewswire.com

8 hours ago

Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

NLTX

businesswire.com

10 hours ago

NEOLEUKIN THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX

NLTX

prnewswire.com

12 hours ago

Shareholder Alert: Ademi LLP investigates whether Neoleukin Therapeutics, Inc. has obtained a Fair Price in its Private Placement and its transaction with Neurogene

NLTX

globenewswire.com

19 hours ago

Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split

NLTX

gurufocus.com

20 hours ago

Redmile Group, LLC Boosts Stake in Neoleukin Therapeutics Inc